این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Research in Medical Sciences، جلد ۲۱، شماره ۱، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome
چکیده انگلیسی مقاله Background: Polycystic ovary syndrome (PCOS) is one of the common endocrine disorders in women of reproductive ages. It is associated with a range of disorders, such as dyslipidemia, hypertension, insulin resistance (IR), compensatory hyperinsulinemia,gestational, and type 2 diabetes, and increased risk of cardiovascular morbidity. There are different treatments available for PCOS. The purpose of this study was to determine and compare the effects of metformin, flutamide plus oral contraceptives (OCs), and simvastatin on the metabolic consequences of PCOS. Materials and Methods: This study was a single-blind clinical trial. The subjects were selected from a group of patient with PCOS and metabolic syndrome, who were referred to the midwifery clinic of Al-Zahra and Beheshti hospitals, Isfahan, Iran. A total of 111 subjects were randomly assigned to three groups: metformin, flutamide plus OCs, and simvastatin groups. The measurements were performed at baseline and after 6 months of therapy. Paired t -test, analysis of variance (ANOVA), and chi-square test were applied in this study. Results: A total of 102 subjects were analyzed in this study, 34 subjects were allotted in each group. The prevalence of IR was statistically diff erent between three groups ( P -value = 0.001). After a 6-month course, metformin showed larger reduction in fasting blood sugar (FBS) level ( P -value < 0.001). However, except for metformin, two other treatments reduced C-reactive protein (CRP) level significantly (both P -values < 0.001). The level of triglycerides (TGs) decreased considerably in all groups (all P -values < 0.001). Both metformin and simvastatin decreased BMI significantly (both P -values < 0.001). None of the treatments changed high-density lipoprotein (HDL) level (all P -values > 0.05). Conclusion: Metformin performed better in FBS reduction. Simvastatin had better performance in terms of reducing TG level and waist circumference.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله فردوس محرابیان | ferdous mehrabian


هتاو قاسمی تهرانی | hatav ghasemi tehrani


محبوبه محمدخانی | mahboobe mohamadkhani


مریم معین الدینی | maryam moeinoddini


پویا کریم زاده | pooya karimzadeh


نشانی اینترنتی http://jrms.mui.ac.ir/index.php/jrms/article/view/10405
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات